PRVA

$22.10

Market ClosedAs of Mar 17, 8:00 PM UTC

Privia Health Group, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$22.10
Potential Downside
84.7%
Whystock Fair Value$3.39
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
122.78
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
4.03%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.55

Recent News

StockStory
Mar 11, 2026

Privia Health (PRVA): Buy, Sell, or Hold Post Q4 Earnings?

Privia Health has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $22.55.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 8, 2026

Privia Health’s EHR Cancer Screening Gains Put Value Based Story In Focus

Privia Health Group (NasdaqGS:PRVA) recently reported major progress in colorectal cancer screening outcomes tied to its EHR integrated patient outreach program. The program has been rolled out at national scale and is linked with screening rates that exceed key benchmarks. The results highlight measurable gains in preventive care that are being achieved through technology focused partnerships. For investors tracking Privia Health Group at a share price of $23.27, this news adds fresh...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 5, 2026

BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide

BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more locations and adds vision services, investors are paying attention to whether its strong brand can drive lasting growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Mar 3, 2026

Privia Health price target raised to $33 from $31 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Privia Health (PRVA) to $33 from $31 and keeps a Buy rating on the shares after hosting management talks. The company noted that the sequential decline in FFS Practice Collections was driven by a higher concentration of specialists versus primary care and specific “retroactive” claims processing timing in the California and North Texas markets, also having suggested that averaging Q3 and Q4 results provides a more accurate represen

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Mar 3, 2026

Vanquis Banking Group PLC (STU:PRVA) Full Year 2025 Earnings Call Highlights: A Return to ...

Vanquis Banking Group PLC (STU:PRVA) reports a significant turnaround with GBP8.3 million profit before tax, exceeding customer interest earning balances, and achieving substantial cost reductions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.